Treatment‐damaged hepatocellular carcinoma promotes activities of hepatic stellate cells and fibrosis through GDF15

[1]  J. Ku,et al.  Metformin increases chemo-sensitivity via gene downregulation encoding DNA replication proteins in 5-Fu resistant colorectal cancer cells , 2017, Oncotarget.

[2]  S. Friedman,et al.  Mechanisms of hepatic stellate cell activation , 2017, Nature Reviews Gastroenterology &Hepatology.

[3]  L. Su,et al.  Metformin disrupts malignant behavior of oral squamous cell carcinoma via a novel signaling involving Late SV40 factor/Aurora-A , 2017, Scientific Reports.

[4]  J. Yang,et al.  Metformin inhibits SUV39H1-mediated migration of prostate cancer cells , 2017, Oncogenesis.

[5]  K. Kuwano,et al.  Metformin attenuates lung fibrosis development via NOX4 suppression , 2016, Respiratory Research.

[6]  A. Kaneda,et al.  Combined Secretomics and Transcriptomics Revealed Cancer-Derived GDF15 is Involved in Diffuse-Type Gastric Cancer Progression and Fibroblast Activation , 2016, Scientific Reports.

[7]  J. Niu,et al.  Association of Serum Level of Growth Differentiation Factor 15 with Liver Cirrhosis and Hepatocellular Carcinoma , 2015, PloS one.

[8]  Yibing Chen,et al.  Transarterial chemoembolization aggravated peritumoral fibrosis via hypoxia‐inducible factor‐1α dependent pathway in hepatocellular carcinoma , 2015, Journal of gastroenterology and hepatology.

[9]  B. Ünal,et al.  The divergent roles of growth differentiation factor-15 (GDF-15) in benign and malignant skin pathologies , 2015, Archives of Dermatological Research.

[10]  S. H. Young,et al.  Dose-Dependent AMPK-Dependent and Independent Mechanisms of Berberine and Metformin Inhibition of mTORC1, ERK, DNA Synthesis and Proliferation in Pancreatic Cancer Cells , 2014, PloS one.

[11]  I. Pernicova,et al.  Metformin—mode of action and clinical implications for diabetes and cancer , 2014, Nature Reviews Endocrinology.

[12]  P. Bourin,et al.  Concise Review: Growth Differentiation Factor 15 in Pathology: A Clinical Role? , 2013, Stem cells translational medicine.

[13]  R. Ramesh,et al.  Mitogen-activated protein kinases and their role in radiation response. , 2013, Genes & cancer.

[14]  E. Garwood,et al.  Morbidity and mortality following transarterial liver chemoembolization in patients with hepatocellular carcinoma and synthetic hepatic dysfunction , 2013, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[15]  Hong Wu,et al.  The influence on liver function after transcatheter arterial chemoembolization combined with percutaneous radiofrequency ablation in patients with hepatocellular carcinoma. , 2012, Journal of the Formosan Medical Association = Taiwan yi zhi.

[16]  R. Evans,et al.  Metformin-Mediated Bambi Expression in Hepatic Stellate Cells Induces Prosurvival Wnt/β-Catenin Signaling , 2012, Cancer Prevention Research.

[17]  James A. Gehl,et al.  Transarterial chemoembolization complicated by deteriorating hepatic function. , 2011, Seminars in interventional radiology.

[18]  M. Lucia,et al.  p53 controls prostate-derived factor/macrophage inhibitory cytokine/NSAID-activated gene expression in response to cell density, DNA damage and hypoxia through diverse mechanisms. , 2009, Cancer letters.

[19]  Xiao-feng He,et al.  A comparative study of damage to liver function after TACE with use of low-dose versus conventional-dose of anticancer drugs in hepatocellular carcinoma. , 2007, Hepato-gastroenterology.

[20]  E. Cholongitas,et al.  Transarterial Therapy for Hepatocellular Carcinoma: Which Technique Is More Effective? A Systematic Review of Cohort and Randomized Studies , 2007, CardioVascular and Interventional Radiology.

[21]  J. Bruix,et al.  Management of hepatocellular carcinoma , 2005, Hepatology.

[22]  H. Rubinfeld,et al.  The ERK cascade , 2005, Molecular biotechnology.

[23]  Ramon Planas,et al.  Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial , 2002, The Lancet.

[24]  John Wong,et al.  Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma , 2002, Hepatology.

[25]  D. Robinson,et al.  Transforming growth factor‐bβ1: its anti‐inflammatory and pro‐fibrotic effects , 2002, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[26]  K. Takeda,et al.  Treatment of hepatocellular carcinoma and the exacerbation of liver function. , 2001, International journal of oncology.

[27]  E. Caturelli,et al.  Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with cirrhosis: evaluation of damage to nontumorous liver tissue-long-term prospective study. , 2000, Radiology.

[28]  A. Jemal,et al.  Cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.

[29]  J. Thrasher,et al.  Macrophage inhibitory cytokine-1: possible bridge molecule of inflammation and prostate cancer. , 2009, Cancer research.

[30]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.